Articles by William Looney - Pharmaceutical Executive

ADVERTISEMENT

Articles by William Looney

William Looney


Articles
Pharm Exec's 2014 Dealmakers Outlook
July 10, 2014

As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead for M&A, licensing, and partnership activity.

The Peace Dividend
July 10, 2014

A surprising takeaway from the recent BIO International Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.

Pharma 50 Trends: Past, Present, and Future
June 9, 2014

Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.

2014 Brand of the Year
May 1, 2014

Pharm Exec's Brand of the Year recipients for 2014 are multiple sclerosis treatment Copaxone and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs.

What's Real in Deals
May 1, 2014

Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.

Mission Critical: Assessing Pharma's Drivers of Change
April 24, 2014

Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.

The FORUM Format
April 7, 2014

With a new name and a veteran CEO, Deborah Dunsire, at the helm, FORUM Pharmaceuticals's flag is waving high in the increasingly solitary struggle against CNS disease.

Dividing Lines
April 1, 2014

Three examples from Pharm Exec's coverage this month show that, in our industry, there are always two sides—at least—to every question.

Population Health: The Call to Community
March 11, 2014

Population health is the foundation for much of what is truly new in US health reform. Pharm Exec talks to Dr. David Nash, Dean of the Jefferson Medical University School of Population Health.

ADVERTISEMENT

Click here